Abstract
Cholecystokinin (CCK) has been implicated as a neurotransmitter, and recent research has identified CCK as having potential antipsychotic effects in patients with chronic schizophrenia. Nine chronic schizophrenic patients with prominent psychotic symptoms and a history of resistance to conventional neuroleptic treatment were administered ceruletide, a synthetic decapeptide of cerulein, intramuscularly. No clinically significant short-term or long-term therapeutic effects were demonstrated, despite the results of statistical analysis which indicated significant improvement. The implications of this open clinical trial for a new treatment modality of chronic schizophrenia are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 485-486 |
| Number of pages | 2 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 46 |
| Issue number | 11 |
| State | Published - Dec 1 1985 |
ASJC Scopus subject areas
- Psychiatry and Mental health
Fingerprint Dive into the research topics of 'Is cholecystokinin therapeutic in chronic schizophrenia?'. Together they form a unique fingerprint.
Cite this
Boza, R. A., & Rotondo, D. J. (1985). Is cholecystokinin therapeutic in chronic schizophrenia? Journal of Clinical Psychiatry, 46(11), 485-486.